|
ALFQ |
Vaxjo ID |
146 |
Vaccine Adjuvant Name |
ALFQ |
Adjuvant VO ID |
VO_0006096
|
Description |
A combination vaccine adjuvant that is an AS01-mimic, liposomal adjuvant of a TLR4 agonist and saponin |
Stage of Development |
Clinical Trial |
Location Licensed |
US (Walter Reed Army Institute of Research) |
Host Species for Testing |
2 |
Second Host Species for Testing |
3 |
Components |
anionic liposomes formed by phospholipids, a synthetic monophosphoryl lipid A analog, 3D-PHAD®; and the immune stimulant QS-21, 1 mL ALFQ solution contains: 200 μg 3-deacyl monophosphoryl lipid A (3D-PHAD®), 7 mg 1,2-dimyristoyl-glycero-3-phosphocholine (DMPC), 0.78 mg 1,2-dimyristoyl-glycero-3-phosphoglycerol (DMPG), 5.4 mg cholesterol and 100 μg QS-21 |
Storage |
Store at 2-8C (do not freeze) |
Function |
MPLA: TLR4 agonist QS21: Sugar-lawn likely recog. by lectins to facilitate uptake by MΏ, DCs, etc |
References |
(Rao, 2023): Vaccine Adjuvant Compendium - VAC [https://vac.niaid.nih.gov/view?id=79]
Hutter et al., 2022: Hutter JN, Robben PM, Lee C, Hamer M, Moon JE, Merino K, Zhu L, Galli H, Quinn X, Brown DR, Duncan E, Bolton J, Zou X, Angov E, Lanar DE, Rao M, Matyas GR, Beck Z, Bergmann-Leitner E, Soisson LA, Waters NC, Ngauy V, Regules J, Dutta S. First-in-human assessment of safety and immunogenicity of low and high doses of Plasmodium falciparum malaria protein 013 (FMP013) administered intramuscularly with ALFQ adjuvant in healthy malaria-naïve adults. Vaccine. 2022; 40(40); 5781-5790. [PubMed: 36055874].
Sei et al., 2021: Sei CJ, Rao M, Schuman RF, Daum LT, Matyas GR, Rikhi N, Muema K, Anderson A, Jobe O, Kroscher KA, Alving CR, Fischer GW. Conserved Influenza Hemagglutinin, Neuraminidase and Matrix Peptides Adjuvanted with ALFQ Induce Broadly Neutralizing Antibodies. Vaccines. 2021; 9(7); . [PubMed: 34202178].
|
|